Optimizing renal anaemia management - Benefits of early referral and treatment

Nephrology Dialysis Transplantation

Volumn 20, Issue SUPPL. 8, 2005, Pages

  Stevens, Paul ^a  

^a KENT AND CANTERBURY HOSPITAL   (United Kingdom)

Author keywords

Anaemia prevalence; Chronic kidney disease; Diabetes; Erythropoietin; Haemoglobin; Iron; Pre dialysis

Indexed keywords

CREATININE; ERYTHROPOIETIN; HEMOGLOBIN; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN;

ANEMIA; BLOOD TRANSFUSION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; COGNITION; COMORBIDITY; CREATININE CLEARANCE; DEATH; DIABETES MELLITUS; DISEASE COURSE; ERYTHROPOIESIS; EVIDENCE BASED MEDICINE; EXERCISE; GLOMERULUS FILTRATION RATE; HEMATOCRIT; HEMODIALYSIS; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; IRON STORAGE; IRON THERAPY; MEDICAL ASSESSMENT; MEDICAL LITERATURE; MORBIDITY; MORTALITY; PATIENT CARE; PATIENT REFERRAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; RISK MANAGEMENT; RISK REDUCTION; SEXUAL BEHAVIOR; SEXUAL FUNCTION; TREATMENT OUTCOME; CHRONIC DISEASE; KIDNEY DISEASE; RENAL REPLACEMENT THERAPY;

ANEMIA; CHRONIC DISEASE; ERYTHROPOIETIN; HEMOGLOBINS; HUMANS; IRON; KIDNEY DISEASES; REFERRAL AND CONSULTATION; RENAL DIALYSIS;

EID: 27744517475     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfh1113     Document Type: Review

References (31)

1. IV. NKF-K/DOQI clinical practice guidelines for anemia of chronic kidney disease: Update 2000. Am J Kidney Dis 2001; 37 [1 Suppl 1]: S182-S238
2. Locatelli F, Aljama P, Barany P et al. European Best Practice Guidelines Working Group. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004; 19 [Suppl 2]: Ii1-ii47
3. Lee GR, Bithell TC, Foerster J et al. Normal blood and bone marrow values in humans. In: Greer JP, Foerster J, Lukens JN, Rodgers GM, Paraskevas F, Glader BE, eds. Wintrobe's Clinical Hematology, 11th edn. Lippincott Williams and Wilkins, Philadelphia, PA; 1993: 2303, Appendix A
4. Whitehead TP, Robinson D, Hale AC, Bailey AR. Clinical Chemistry and Haematology: Adult Reference Values. BUPA Medical Research, London 1994: 48-49
5. Waalen J, Felitti V, Beutler E. Haemoglobin and ferritin concentrations in men and women: Cross sectional study. Br Med J 2002; 325: 137
6. Levin A, Thompson CR, Ethier J et al. Left ventricular mass index increase in early renal disease: Impact of decline in hemoglobin. Am J Kidney Dis 1999; 34: 125-134
7. Astor BC, Muntner P, Levin A, Eustace JA, Coresh J. Association of kidney function with anemia: The Third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med 2002; 162: 1401-1408
8. John R, Webb M, Young A, Stevens PE. Unreferred chronic kidney disease: a longitudinal study. Am J Kidney Dis 2004; 43: 825-835
9. de Lusignan S, Chan T, Stevens P et al. Identifying patients with chronic kidney disease from general practice computer records. Fam Pract 2005; 22: 234-241
10. Stevens PE, O'Donoghue DJ, Lameire NR. Anaemia in patients with diabetes: Unrecognised, undetected and untreated? Curr Med Res Opin 2003; 19: 395-401
11. Thomas MC, MacIsaac RJ, Tsalamandris C, Power D, Jerums G. Unrecognized anaemia in patients with diabetes. Diabetes Care 2003; 26: 1164-1169
12. John RI, Webb MC, Young A, Stevens PE. Anaemia in diabetes - under recognised and under treated (Abstracts of the 18th International Diabetes Federation Congress). Diabetes Metab 2003; 29 [Spec no 2]: 457-464
13. Hsu C, McCulloch CE, Curhan GC. Iron status and haemoglobin level in chronic renal insufficiency. J Am Soc Nephrol 2002; 13: 2783-2786
14. Nissenson AR, Charytan C. Controversies in iron management. Kidney Int 2003; 64 [Suppl 87]: S64-S71
15. Besarab A, Bolton WK, Browne JK et al. The effects of normal as compared to low haematocrit values in patients with cardiac disease who are receiving haemodialysis and epoetin. N Engl J Med 1998; 339: 584-590
16. Strippoli GFM. Hemoglobin targets for the anemia of chronic kidney disease: A meta-analysis of randomized controlled trials. J Am Soc Nephrol 2004; 15: 3154-3165
17. Silberberg J, Racine N, Barre P, Sniderman AD. Regression of left ventricular hypertrophy in dialysis patients following correction of anaemia with recombinant human erythropoietin. Can J Cardiol 1990; 6: 1-4
18. Hayashi T, Suzuki A, Shoji T et al. Cardiovascular effect of normalizing the haematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure. Am J Kidney Dis 2000; 35: 250-256
19. Portoles J, Torralbo A, Martin P, Rodrigo J, Herrero JA, Barrientos A. Cardiovascular effects of recombinant erythropoietin in predialysis patients. Am J Kidney Dis 1997; 29: 541-548
20. Li S, Collins AJ. Association of hematocrit value with cardiovascular morbidity and mortality in incident hemodialysis patients. Kidney Int 2004; 65: 626-633
21. Barany P, Divino Filho JC, Bergstrom J. High C-reactive protein is a strong predictor of resistance to erythropoietin in hemodialysis patients. Am J Kidney Dis 1997; 29: 565-568
22. Gunnell J, Yeun JY, Depner TA, Kaysen GA. Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients. Am J Kidney Dis 1999; 33: 63-72
23. Kato A, Odamaki M, Takita T, Furuhashi M, Maruyama Y, Hishida A. High blood soluble receptor p80 for tumour necrosis factor-alpha is associated with erythropoietin resistance in haemodialysis patients. Nephrol Dial Transplant 2001; 16: 1838-1844
24. Sezer S, Kulah E, Ozdemir FN, Tutal E, Arat Z, Haberal M. Clinical consequences of intermittent elevation of C-reactive protein levels in hemodialysis patients. Transplant Proc 2004; 36: 38-40
25. Silverberg DS, Wexler D, Blum M et al. The effect of correction of anaemia in diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron Nephrol Dial Transplant 2003; 18: 141-146
26. Kuriyama S, Tomonari H, Yoshida H, Hashimoto T, Kawaguchi Y, Sakai O. Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron 1997; 77: 176-185
27. Gouva C, Nikolopoulos P, Ionnidis JP, Siamopoulos KC. Treating anemia early in renal failure patients slows the decline of renal function: A randomized controlled trial. Kidney Int 2004; 66: 753-760
28. Roger SD, McMahon LP, Clarkson A et al. Effects of early and late intervention with epoetin alpha on left ventricular mass among patients with chronic kidney disease (stage 3 or 4): Results of a randomized clinical trial. J Am Soc Nephrol 2004; 15: 148-156
29. Eckardt KU. The CREATE trial - building the evidence. Nephrol Dial Transplant 2001; 16 [Suppl 2]: 16-18
30. Reddan D, Singh AK. Can risk factor modification provide meaningful benefit? The correction of hemoglobin and outcomes in renal insufficiency (CHOIR) study. Presented at - The American Society of Nephrology Renal Week; San Diego, CA; November 12-17, 2003
31. Rao M, Pereira BJ. Prospective trials on anemia of chronic kidney disease: The trial to reduce cardiovascular events with Aranesp therapy (TREAT). Kidney Int 2003; 65 [Suppl 87]: S12-S19